Roche's Actemra Helps the Sickest COVID-19 Patients, Study Shows Roche's Actemra Helps the Sickest COVID-19 Patients, Study Shows
Roche ' s Actemra helped the sickest COVID-19 patients in a 303-patient study, the trial ' s lead investigator said on Thursday, bolstering what has been mixed evidence that the arthritis drug can be repurposed to help in the pandemic.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - November 23, 2020 Category: Intensive Care Tags: Infectious Diseases News Source Type: news

Tocilizumab: Arthritis drug may treat severe Covid
Early signs suggest it may help patients with severe breathing difficulties who are on ventilators. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - November 19, 2020 Category: Consumer Health News Source Type: news

Arthritis drug tocilizumab can help critically-ill Covid patients recover, trial finds
Patients given the drug in the REMAP-CAP trial, led by Imperial College London, were 87 per cent more likely to see their illness improve than those not given the drug. (Source: the Mail online | Health)
Source: the Mail online | Health - November 19, 2020 Category: Consumer Health News Source Type: news

Tocilizumab Stumbles as COVID-19 Treatment, Narrow Role Possible Tocilizumab Stumbles as COVID-19 Treatment, Narrow Role Possible
New randomized controlled trial data show tocilizumab has a narrow role at best for treating COVID-19.Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - October 28, 2020 Category: Infectious Diseases Tags: Infectious Diseases News Source Type: news

Drug vignettes: Tocilizumab, CEBM (Updated 26th October 2020)
Patients with severe COVID-19 can develop cytokine release syndrome ( “cytokine storm”) and are 2 External 0 0 0 reported false https://www.medrxiv.org/content/10.1101/2020.03.01.20029769v2.full.pdf true false%> to have high circulating IL-6 concentrations. Tocilizumab is a recombinant humanized anti-human IgG1 monoclonal antibody directed against the interleukin-6 receptor (IL-6R). It has therefore been proposed to be of value in the management of severe COVID-19. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - October 28, 2020 Category: Consumer Health News Source Type: news

Oct 23 2020 This Week in Cardiology Oct 23 2020 This Week in Cardiology
COVID, tocilizumab, hypertrophic cardiomyopathy, cerebral microbleeds, and surrogate endpoints are the topics discussed by John Mandrola, MD, in this week ’ s podcasttheheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 23, 2020 Category: Consumer Health News Tags: Cardiology Commentary Source Type: news

Findings Conflicted for Benefit of Tocilizumab in COVID - 19
One trial shows reduction in mortality, but no evidence of efficacy seen in two additional trials (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - October 23, 2020 Category: Respiratory Medicine Tags: Infections, Internal Medicine, Critical Care, Nursing, Pharmacy, Pulmonology, Rheumatology, Journal, Source Type: news

Findings Conflicted for Benefit of Tocilizumab in COVID-19
FRIDAY, Oct. 23, 2020 -- Tocilizumab may be beneficial for adults with COVID-19 admitted to the intensive care unit (ICU), although other findings are conflicting, according to three studies and an editorial published online Oct. 20 in JAMA Internal... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 23, 2020 Category: Pharmaceuticals Source Type: news

Tocilizumab Does Not Prevent Intubation, Death in COVID - 19
Intubation or death, disease worsening similar for tocilizumab, placebo in hospitalized patients (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - October 22, 2020 Category: Respiratory Medicine Tags: Infections, Nursing, Pharmacy, Pulmonology, Critical Care, Emergency Medicine, Journal, Source Type: news

Tocilizumab Does Not Prevent Intubation, Death in COVID-19
THURSDAY, Oct. 22, 2020 -- For moderately ill hospitalized patients with COVID-19, tocilizumab is not effective for preventing intubation or death, according to a study published online Oct. 21 in the New England Journal of Medicine. John H. Stone,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 22, 2020 Category: Pharmaceuticals Source Type: news

Study finds tocilizumab improves survival in critically ill patients with COVID-19
Researchers from 68 sites across the country, led by David E. Leaf, MD, MMSc and Shruti Gupta, MD, MPH from the Division of Renal Medicine at Brigham and Women's Hospital, have investigated the effects of the anti-inflammatory drug tocilizumab on critically ill patients with laboratory-confirmed COVID-19. Unlike steroids, which suppress the immune system more broadly, tocilizumab specifically inhibits the receptor for the pro-inflammatory cytokine, IL-6. (Source: World Pharma News)
Source: World Pharma News - October 21, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Tocilizumab doesn't ease symptoms or prevent death in moderately ill COVID-19 inpatients
(Massachusetts General Hospital) The drug tocilizumab (Actemra) does not reduce the need for breathing assistance with mechanical ventilation or prevent death in moderately ill hospitalized patients with COVID-19, according to a study by researchers at Massachusetts General Hospital. The study, published in the New England Journal of Medicine, casts doubt on earlier research suggesting that tocilizumab, which is commonly prescribed for rheumatoid arthritis and other conditions, might be an effective treatment for patients with worsening cases of COVID-19. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - October 21, 2020 Category: Infectious Diseases Source Type: news

New results from a once-promising therapy show the difficulty of treating covid-19
The drug, tocilizumab, showed early potential but evidence since then has been conflicting. (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - October 20, 2020 Category: Consumer Health News Authors: Ben Guarino Source Type: news

Study: Tocilizumab reduces risk for death in hospitalized patients with severe COVID-19
Treatment with the rheumatoid arthritis drug tocilizumab, sold as Actemra, reduces risk for death among hospitalized patients with severe COVID-19 by about 30%, a study published Tuesday by JAMA Internal Medicine found. (Source: Health News - UPI.com)
Source: Health News - UPI.com - October 20, 2020 Category: Consumer Health News Source Type: news

Efficacy of Tocilizumab in Patients With COVID-19 ARDS Efficacy of Tocilizumab in Patients With COVID-19 ARDS
How effective is tocilizumab therapy in patients who develop severe COVID-related ARDS?Critical Care (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 20, 2020 Category: Consumer Health News Tags: Critical Care Journal Article Source Type: news